LEADER 02306nam  2200589 a 450 
001 9910437851503321
005 20200520144314.0
010   $a1-283-69722-X
010   $a1-4614-5206-6
024 7 $a10.1007/978-1-4614-5206-5
035   $a(CKB)2670000000277740
035   $a(EBL)1030892
035   $a(OCoLC)813837900
035   $a(SSID)ssj0000790048
035   $a(PQKBManifestationID)11428973
035   $a(PQKBTitleCode)TC0000790048
035   $a(PQKBWorkID)10737534
035   $a(PQKB)10122293
035   $a(DE-He213)978-1-4614-5206-5
035   $a(MiAaPQ)EBC1030892
035   $a(PPN)168302349
035   $a(EXLCZ)992670000000277740
100   $a20120830d2013      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCave microbiomes $ea novel resource for drug discovery /$fNaowarat Cheeptham, editor
205   $a1st ed. 2013.
210   $aNew York $cSpringer$d2013
215   $a1 online resource (142 p.)
225  0$aSpringerBriefs in microbiology,$x2191-5385
300   $aDescription based upon print version of record.
311   $a1-4614-5205-8 
320   $aIncludes bibliographical references.
327   $aAdvances and Challenges in Studying Cave Microbial Diversity -- Cave Biofilms and Their Potential for Novel Antibiotic Discovery -- Cave Conservation: A Canadian caver's Perspective -- Cave Conversation: A Microbiologist's Perspective -- Microbial Ecology: Caves as an Extreme Habitat -- Studies of Antibiotic Production by Cave Bacteria.  .
330   $aThis book details recent findings in the field of cave microbiology and builds on fast-paced efforts to exploit an unconventional and underexplored environment for new microorganisms which may provide an untapped source of drugs: microorganisms from caves.
410  0$aSpringerBriefs in Microbiology,$x2191-5385 ;$v1
606   $aCaves$xMicrobiology
606   $aDrug development
615  0$aCaves$xMicrobiology.
615  0$aDrug development.
676   $a615.101579
701   $aCheeptham$b Naowarat$01751922
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910437851503321
996   $aCave microbiomes$94187066
997   $aUNINA